Beijing Huarui Dingxin Technology Co., Ltd

Main objectives: 1. To evaluate the safety and tolerability of HRN01 tablets after single and multiple oral administration in healthy subjects; 2. To evaluate the effect of food (high-fat and high-calorie meal) on the pharmacokinetics of HRN01 tablets. Secondary objectives: 1. To evaluate the pharmacokinetic characteristics of HRN01 tablets after single and multiple oral administration in healthy subjects; 2. To evaluate the metabolism and excretion characteristics of HRN01 tablets in healthy subjects; 3. To evaluate the effect of single administration of HRN01 tablets on the QTc interval of healthy subjects; 4. To evaluate the safety and tolerability of oral administration of HRN01 tablets in healthy subjects in the postprandial state (high-fat and high-calorie meal). Exploratory objectives: To explore the pharmacodynamic indicators of HRN01 tablets after multiple oral administration in healthy subjects.

To evaluate the efficacy and safety of dextrabeprazole sodium for injection in the treatment of acute non-variceal upper gastrointestinal bleeding

This study aimed to investigate the pharmacokinetic characteristics of a single fasting and postprandial oral administration of cefixime granules (50 mg) developed by Beijing Huarui Dingxin Technology Co., Ltd. and produced by North China Pharmaceutical Hebei Huamin Pharmaceutical Co., Ltd.; using cefixime fine granules (Cefspan®, 50 mg) produced by Changshengtang Pharmaceutical Co., Ltd. as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and to evaluate the bioequivalence of the two preparations in humans.